Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM)
Autor: | Geir Selbæk, Bettina S. Husebo, Elisabeth Flo, Ane Erdal, Dag Aarsland, Dagrun D. Slettebo, Clive Ballard |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Male
medicine.medical_specialty drug safety Analgesic Population Placebo-controlled study Pain Placebo Administration Cutaneous 03 medical and health sciences 0302 clinical medicine Drug Delivery Systems Internal medicine medicine Humans 030212 general & internal medicine Adverse effect education Original Research Aged Pain Measurement education.field_of_study adverse drug reactions business.industry opioids General Medicine Discontinuation Buprenorphine Nursing Homes Analgesics Opioid Tolerability Clinical Interventions in Aging analgesics Female Dementia Geriatrics and Gerontology business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Clinical Interventions in Aging |
ISSN: | 1178-1998 |
Popis: | Ane Erdal,1 Elisabeth Flo,2 Dag Aarsland,3,4 Geir Selbaek,5–7 Clive Ballard,8 Dagrun D Slettebo,1 Bettina S Husebo1,9 1Department of Global Public Health and Primary Care, Centre for Elderly and Nursing Home Medicine, University of Bergen, Bergen, Norway; 2Department of Clinical Psychology, University of Bergen, Bergen, Norway; 3Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 4Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; 5Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway; 6National Advisory Unit on Aging and Health, Tønsberg, Norway; 7Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway; 8Exeter Medical School, University of Exeter, Exeter, UK; 9Municipality of Bergen, Bergen, Norway Purpose: Buprenorphine transdermal system is increasingly prescribed in people with advanced dementia, but no clinical trial has investigated the safety and factors associated with discontinuation due to adverse events in this population. Patients and methods: One hundred sixty-two people with advanced dementia and significant depression from 47 nursing homes were included and randomized to active analgesic treatment (acetaminophen/buprenorphine) or identical placebo for 13 weeks. In this secondary analysis, the main outcomes were time to and reasons for discontinuation of buprenorphine due to adverse events. Change in daytime activity as measured by actigraphy was a secondary outcome. Results: Of the 44 patients who received active buprenorphine 5 μg/hour, 52.3% (n=23) discontinued treatment due to adverse events compared to 13.3% (6 of 45) in the placebo group (p |
Databáze: | OpenAIRE |
Externí odkaz: |